Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
A Phase II study of intravenous exatecan administered daily for 5 days
It contains trifluridine (TFT) and Tipiracil hydrochloride (TTP) in a molar ratio of 1
Formula: C13H14Cl3N7O4
The (Z)-isomer has been consigned the name BMS-205912
WAY-200070 (30 mg/kg s
PF-06463922 5109 HCl A Phase II study ofLorlatinib, also known as PF 06463922, is an orally available, ATP competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, ALK ROS1 inhibitor PF 06463922 binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK and ROS1 mediated signaling and eventually inhibits tumor cell growth in ALK and